Revive Therapeutics approved by FDA for Phase 3 trial of possible Covid-19 treatment

Mugglehead
By Jared GnamJul 31, 2020, 7:46 pm306 pts
Novel drug developer Revive Therapeutics Ltd. (CSE: RVV) hit a major milestone this week receiving U.S. Food and Drug Administration approval to begin a Phase 3 trial of its lead drug Bucillamine to treat patients with Covid-19. On Friday, the Toronto-based company said the confirmatory Phase 3 clinical will be…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Pura Vida! Costa Rica officially starts medical cannabis rollout after years of delays 68

Congressional Committee Approves Federal Hemp THC Ban That Stakeholders Say Would Decimate Industry 57

Mature cannabis markets see job losses while emerging states boom 55

Jones Soda calls it quits with Mary Jones, sells canna-beverage biz for US$3M 45

What craft and micro producers are doing to stay profitable in a turbulent market 36

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.